FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	······································														OMB APPRO		AL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STATE	ATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								RSH	IP	11	r: 3 erage burden ponse:	235-0287 0.5	
transac contrac the pur securiti to satis	chase or sale of ies of the issue of the affirmative ons of Rule 10b	pursuant to a written plan for of equity that is intended we defense															
1. Name and Address of Reporting Person [*] SEMBER MICHAEL T					2. Issuer Name and Ticker or Trading Symbol <u>Quoin Pharmaceuticals, Ltd.</u> [QNRX]								ationship of all applica Director	able)	Reporting Person(s) to Issuer le) 10% Owner		
(Last) (First) (Middle) C/O QUOIN PHARMACEUTICALS LTD.,					3. Date of Earliest Transaction (Month/Day/Year) 12/09/2024								Officer (below)	give title	ve title Other (speci below)		ecify
42127 PLEASANT FOREST COURT (Street) ASHBURN VA 20148				4.	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Inc Line)								,				
(City) (State) (Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) Date (Month/					action 2A. Deemed Execution Date, if any (Month/Day/Year			Transaction Disposed		ies Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amoun Securities Beneficial Owned Fo	s Form Ily (D) ollowing (I) (I		Direct In Indirect B str. 4) 0	7. Nature of Indirect Beneficial Ownership
								Code V	Amount	(A) c (D)	Pric	rice Reported Transaction (Instr. 3 and				((Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares			(Instr. 4)	511(3)		
Share Option (Right to Buy)	\$ 0.78 ⁽¹⁾	12/09/2024		A		50,714 ⁽¹⁾		(2)	12/09/2034	ADS ⁽¹⁾	50,714	4 (1)	\$ 0 50,714 ⁽¹⁾		(1)	D	

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.

 /s/ Michael Sember
 12/10/2024

 ** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.